Niraparib plus Pembrolizumab (Pembro) Versus Placebo + Pembro 1L Maintenance Therapy in Advanced NSCLC: ZEAL-1L Phase III Study

被引：0
|
作者：
Ramalingam, S. [1 ]
Arora, S. [2 ]
Neibauer, M. Whipple [2 ]
Zhou, J. [2 ]
Hazard, S. [3 ]
Frenkl, T. [2 ]
Stojadinovic, A. [2 ]
Peters, S. [4 ]
机构：
[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[2] Glaxosmithkline, Philadelphia, PA USA
[3] Glaxosmithkline, Waltham, MA USA
[4] Lausanne Univ, Oncol, Lausanne, Switzerland
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
NSCLC; PARP inhibitor; niraparib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P83.02
引用
收藏
页码：S653 / S654
页数：2
相关论文
共 50 条
  • [31] Coformulated quavonlimab and pembrolizumab (pembro) in combination with lenvatinib (lenva) as first-line (1L) therapy for patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 2 KEYSTEP-004 study.
    Rimassa, Lorenza
    Li, Daneng
    Ikeda, Masafumi
    Yarchoan, Mark
    Ryoo, Baek-Yeol
    Kossler, Thibaud
    Lim, Ho-Yeong
    Kwiatkowski, Mariusz
    Chang, Ting-Tsung
    Kim, Jee Hyun
    Casadei-Gardini, Andrea
    Kudo, Masatoshi
    Ren, Zhenggang
    Calvo, Maria Varela
    Llovet, Josep M.
    Zhang, Yayan
    Hatogai, Ken
    Siegel, Abby B.
    Cheng, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 484 - 484
  • [32] Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799.
    Jabbour, Salma K.
    Lee, Ki Hyeong
    Frost, Nicolaj
    Kowalski, Dariusz
    Breder, Valeriy Vladimirovich
    Pollock, Theodore
    Reguart, Noemi
    Houghton, Baerin
    Quantin, Xavier
    Keller, Steven M.
    Liu, Hong
    Piperdi, Bilal
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] Association of TMB and PD-L1 with efficacy of first-line pembrolizumab (pembro) or pembro plus chemotherapy (chemo) versus chemo in patients (pts) with advanced urothelial carcinoma (UC) from KEYNOTE-361.
    Morales-Barrera, Rafael
    Powles, Thomas
    Ozguroglu, Mustafa
    Csoszi, Tibor
    Loriot, Yohann
    Flechon, Aude
    Matsubara, Nobuaki
    Rodriguez-Vida, Alejo
    Geczi, Lajos
    Cheng, Susanna Y.
    Fradet, Yves
    Oudard, Stephane
    Gunduz, Seyda
    Ma, Junshui
    Rajasagi, Mohini
    Vajdi, Amir
    Cristescu, Razvan
    Imai, Kentaro
    Moreno, Blanca Homet
    Alva, Ajjai Shivaram
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [34] KEYNOTE 029: Phase 1/2 randomized study of pembrolizumab (pembro) plus 2 dose regimens of ipilimumab (ipi) for advanced melanoma
    Atkins, M. B.
    Carlino, M. S.
    Hill, A. G.
    McNeil, C. M.
    Ribas, A.
    Atkinson, V.
    Cebon, J. S.
    Jameson, M. B.
    Hwu, W-J.
    Thompson, J. A.
    Anderson, J.
    Moreno, B. Homet
    Ibrahim, N.
    Long, G. V.
    ANNALS OF ONCOLOGY, 2017, 28
  • [35] Phase III study of pembrolizumab (pembro) plus enzalutamide (enza) versus placebo plus enza for metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-641
    Graff, Julie Nicole
    Burgents, Joseph
    Liang, Li Wen
    Stenzl, Arnulf
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [36] Pembrolizumab Plus Ipilimumab or Placebo in 1L Metastatic NSCLC with PD-L1 Tumor Proportion Score (TPS) ≥50%: KEYNOTE-598
    Boyer, M.
    Mclean, J.
    Xu, L.
    Samkari, A.
    Carbone, D.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S462 - S462
  • [37] ASCENT-04/KEYNOTE-D19: Phase III study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs treatment of physician's choice (TPC) plus pembro in first-line (1L) programmed death-ligand 1-positive (PD-L1+) metastatic triple-negative breast cancer (mTNBC)
    Tolaney, S. M.
    De Azambuja, E.
    Emens, L. A.
    Loi, S.
    Pan, W.
    Huang, J.
    Sun, S. W.
    Lai, C.
    Schmid, P.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S664 - S665
  • [38] IMpower151: Phase III Study of Atezolizumab plus Bevacizumab plus Chemotherapy in 1L Metastatic Nonsquamous NSCLC
    Zhou, C.
    Dong, X.
    Chen, G.
    Wang, Z.
    Wu, X.
    Yao, Y.
    Zhang, Y.
    Cheng, Y.
    Pan, H.
    Zhang, X.
    Cui, J.
    Wang, L.
    Chen, X.
    Li, X.
    Wang, Z.
    Wang, Q.
    He, J.
    Wang, M.
    Yan, I.
    Qian, L.
    An, A.
    Cai, A.
    Wu, Q.
    Ballinger, M.
    Wang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S64 - S65
  • [39] Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)
    Finn, R. S.
    Kudo, M.
    Merle, P.
    Meyer, T.
    Qin, S.
    Ikeda, M.
    Xu, R.
    Edeline, J.
    Ryoo, B-Y.
    Ren, Z.
    Cheng, A-L.
    Galle, P. R.
    Kaneko, S.
    Kumada, H.
    Wang, A.
    Mody, K.
    Dubrovsky, L.
    Siegel, A. B.
    Llovet, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1401 - S1401
  • [40] Phase 1/2 study of pembrolizumab (pembro) in children with advanced melanoma or a PD-L1-positive (PD-L+) advanced, relapsed, or refractory solid tumor or lymphoma (KEYNOTE-051).
    Geoerger, Birgit
    Fox, Elizabeth
    Pappo, Alberto S.
    Oren, Michael Yalon
    Marshall, Lynley V.
    Heath, Karl
    Diede, Scott J.
    Ebbinghaus, Scot
    Park, Julie R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345